Go Pro
→ The pact that ran the world and dollar just expired (From Golden Portfolio) (Ad)tc pixel Free BMEA Stock Alerts

Biomea Fusion (BMEA) Financials

Biomea Fusion logo
$1.25 -0.01 (-0.79%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.25 +0.00 (+0.40%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Biomea Fusion

Annual Income Statements for Biomea Fusion

This table shows Biomea Fusion's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.20 -5.32 -42 -82 -117 -138 -62
Consolidated Net Income / (Loss)		 -1.20 -5.32 -42 -82 -117 -138 -62
Net Income / (Loss) Continuing Operations		 -1.20 -5.32 -42 -82 -117 -138 -62
Total Pre-Tax Income 		-1.20 -5.32 -42 -82 -117 -138 -62
Total Operating Income		 -1.20 -5.33 -42 -84 -126 -144 -84
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 1.20 5.33 42 84 126 144 84
Selling, General & Admin Expense		 0.10 1.66 14 21 24 26 19
Research & Development Expense		 1.09 3.67 28 63 103 118 62
Impairment Charge		 - - - - 0.00 0.00 2.21
Total Other Income / (Expense), net		 0.00 0.00 0.10 1.81 8.88 5.64 22
Interest & Investment Income		 - 0.00 0.10 1.81 8.88 5.64 1.86
Other Income / (Expense), net		 - - - - - - 20
Basic Earnings per Share		 ($0.20) ($0.51) ($1.74) ($2.80) ($3.44) ($3.83) ($1.18)
Weighted Average Basic Shares Outstanding		 6.05M 10.53M 23.86M 29.27M 34.11M 36.11M 52.23M
Diluted Earnings per Share		 ($0.20) ($0.51) ($1.74) ($2.80) ($3.44) ($3.83) ($1.18)
Weighted Average Diluted Shares Outstanding		 6.05M 10.53M 23.86M 29.27M 34.11M 36.11M 52.23M
Weighted Average Basic & Diluted Shares Outstanding		 6.05M 10.53M 23.86M 29.61M 35.89M 37.57M 72.30M

Quarterly Income Statements for Biomea Fusion

This table shows Biomea Fusion's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -28 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12
Consolidated Net Income / (Loss)		 -28 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12
Net Income / (Loss) Continuing Operations		 -28 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12
Total Pre-Tax Income 		-28 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12
Total Operating Income		 -31 -37 -41 -39 -34 -30 -30 -21 -21 -12 -13
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 31 37 41 39 34 30 30 21 21 12 13
Selling, General & Admin Expense		 5.77 6.46 7.28 7.07 6.80 4.83 6.82 4.71 4.20 3.60 3.65
Research & Development Expense		 25 31 34 32 27 25 23 17 14 8.12 9.12
Total Other Income / (Expense), net		 2.69 2.44 2.00 1.62 1.25 0.77 0.45 0.54 4.40 16 0.43
Interest & Investment Income		 2.69 2.44 2.00 1.62 1.25 0.77 0.45 0.54 4.40 -3.53 0.43
Basic Earnings per Share		 ($0.80) ($0.96) ($1.09) ($1.03) ($0.91) ($0.80) ($0.80) ($0.51) ($0.27) $0.40 ($0.17)
Weighted Average Basic Shares Outstanding		 35.65M 34.11M 35.89M 36.04M 36.22M 36.11M 36.63M 40.63M 59.85M 52.23M 72.30M
Diluted Earnings per Share		 ($0.80) ($0.96) ($1.09) ($1.03) ($0.91) ($0.80) ($0.80) ($0.51) ($0.27) $0.40 ($0.17)
Weighted Average Diluted Shares Outstanding		 35.65M 34.11M 35.89M 36.04M 36.22M 36.11M 36.63M 40.63M 59.85M 52.23M 72.30M
Weighted Average Basic & Diluted Shares Outstanding		 35.71M 35.89M 35.94M 36.21M 36.24M 37.57M 37.57M 59.51M 70.70M 72.30M 72.30M

Annual Cash Flow Statements for Biomea Fusion

This table details how cash moves in and out of Biomea Fusion's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 61 84 -34 65 -119 -2.47
Net Cash From Operating Activities		 -4.46 -35 -62 -97 -120 -70
Net Cash From Continuing Operating Activities		 -4.46 -35 -62 -97 -120 -70
Net Income / (Loss) Continuing Operations		 -5.32 -42 -82 -117 -138 -62
Consolidated Net Income / (Loss)		 -5.32 -42 -82 -117 -138 -62
Depreciation Expense		 0.01 0.25 0.69 1.52 1.75 1.41
Amortization Expense		 0.00 1.22 0.14 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.45 6.23 11 17 22 -6.29
Changes in Operating Assets and Liabilities, net		 0.41 -1.57 7.67 2.33 -5.15 -3.70
Net Cash From Investing Activities		 -0.05 -33 27 -2.22 -0.36 0.00
Net Cash From Continuing Investing Activities		 -0.05 -33 27 -2.22 -0.36 0.00
Purchase of Property, Plant & Equipment		 -0.05 -3.17 -1.03 -3.37 -0.36 0.00
Sale and/or Maturity of Investments		 0.00 8.31 28 1.15 0.00 0.00
Net Cash From Financing Activities		 66 153 1.24 164 1.67 68
Net Cash From Continuing Financing Activities		 66 153 1.24 164 1.67 68
Issuance of Common Equity		 10 153 1.24 164 1.67 68

Quarterly Cash Flow Statements for Biomea Fusion

This table details how cash moves in and out of Biomea Fusion's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -24 -22 -32 -32 -25 -30 -22 20 -9.58 9.17 -11
Net Cash From Operating Activities		 -24 -23 -32 -33 -25 -30 -26 -19 -12 -14 -12
Net Cash From Continuing Operating Activities		 -24 -23 -32 -33 -25 -30 -26 -19 -12 -14 -12
Net Income / (Loss) Continuing Operations		 -28 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12
Consolidated Net Income / (Loss)		 -28 -35 -39 -37 -33 -29 -29 -21 -16 4.61 -12
Depreciation Expense		 0.42 0.42 0.42 0.42 0.44 0.47 0.47 0.47 0.43 0.05 0.00
Amortization Expense		 - - 1.00 -1.00 - - 0.77 -0.77 - - 0.00
Non-Cash Adjustments To Reconcile Net Income		 4.29 4.57 5.02 6.22 5.46 5.23 3.17 3.90 0.39 -14 1.65
Changes in Operating Assets and Liabilities, net		 -0.18 7.05 0.59 -1.01 1.67 -6.40 -0.81 -2.08 4.04 -4.85 -0.95
Net Cash From Investing Activities		 -0.04 -0.01 -0.04 -0.06 -0.19 -0.08 0.00 - - - 0.55
Net Cash From Continuing Investing Activities		 -0.04 -0.01 -0.04 -0.06 -0.19 -0.08 0.00 - - - 0.55
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.55
Net Cash From Financing Activities		 0.14 0.62 0.12 1.07 0.07 0.41 3.25 40 1.97 23 0.00
Net Cash From Continuing Financing Activities		 0.14 0.62 0.12 1.07 0.07 0.41 3.25 40 1.97 23 0.00
Repayment of Debt		 - - 0.00 - - - -0.01 -0.12 -0.63 - 0.00
Issuance of Common Equity		 0.14 0.62 0.00 1.19 0.07 0.41 3.26 40 2.60 22 0.00

Annual Balance Sheets for Biomea Fusion

This table presents Biomea Fusion's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 63 186 129 200 80 59
Total Current Assets		 62 177 118 179 68 58
Cash & Equivalents		 62 146 112 177 58 56
Restricted Cash		 0.00 - 0.35 0.37 0.37 0.00
Prepaid Expenses		 0.53 3.05 4.77 2.32 10 2.24
Plant, Property, & Equipment, net		 0.08 2.97 5.84 5.16 3.77 0.15
Total Noncurrent Assets		 0.22 6.18 5.30 15 7.47 0.37
Long-Term Investments		 0.00 1.88 0.00 - - 0.00
Other Noncurrent Operating Assets		 0.22 4.30 5.30 15 7.47 0.37
Total Liabilities & Shareholders' Equity		 63 186 129 200 80 59
Total Liabilities		 1.62 6.92 21 31 28 29
Total Current Liabilities		 1.62 4.64 19 23 22 11
Accounts Payable		 0.73 1.33 6.83 6.85 13 3.23
Accrued Expenses		 0.63 2.74 12 14 6.66 6.41
Other Current Liabilities		 0.22 0.57 0.62 2.47 2.08 1.46
Total Noncurrent Liabilities		 0.00 2.29 1.67 7.83 6.69 18
Other Noncurrent Operating Liabilities		 0.00 2.29 1.67 7.83 6.69 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.17 179 109 169 52 30
Total Preferred & Common Equity		 5.17 179 109 169 52 30
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 5.17 179 109 169 52 30
Common Stock		 13 229 240 418 439 479
Retained Earnings		 -8.18 -50 -132 -249 -387 -449
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.01 -0.00 - - 0.00

Quarterly Balance Sheets for Biomea Fusion

This table presents Biomea Fusion's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 225 168 136 110 55 73 55 46
Total Current Assets		 203 148 116 94 45 65 49 46
Cash & Equivalents		 199 145 113 88 36 56 47 45
Restricted Cash		 0.37 0.37 0.37 0.37 0.37 - 0.37 0.37
Prepaid Expenses		 3.41 2.65 3.00 5.65 8.82 8.44 2.80 1.26
Plant, Property, & Equipment, net		 5.58 4.81 4.45 4.23 3.30 2.83 0.20 0.07
Total Noncurrent Assets		 17 16 15 12 6.70 5.67 5.18 0.00
Long-Term Investments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 17 16 15 12 6.70 5.67 5.18 0.00
Total Liabilities & Shareholders' Equity		 225 168 136 110 55 73 55 46
Total Liabilities		 25 33 32 34 26 46 40 28
Total Current Liabilities		 16 25 25 28 20 18 16 9.29
Accounts Payable		 3.19 4.71 5.83 8.99 7.71 8.38 6.40 4.61
Accrued Expenses		 10 17 16 16 11 8.44 8.38 3.44
Other Current Liabilities		 2.83 3.17 3.29 2.69 1.43 0.76 0.79 1.24
Total Noncurrent Liabilities		 9.27 7.93 7.05 6.88 6.50 28 24 18
Other Noncurrent Operating Liabilities		 9.27 7.93 7.05 6.88 6.50 28 24 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 200 135 104 76 29 28 16 19
Total Preferred & Common Equity		 200 135 104 76 29 28 16 19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 200 135 104 76 29 28 16 19
Common Stock		 414 423 429 434 445 465 469 480
Retained Earnings		 -214 -288 -325 -358 -417 -437 -454 -461
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00

Annual Metrics And Ratios for Biomea Fusion

This table displays calculated financial ratios and metrics derived from Biomea Fusion's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 29,044,784.00 29,396,246.00 35,705,786.00 - 70,703,639.00
DEI Adjusted Shares Outstanding		 0.00 0.00 29,044,784.00 29,396,246.00 35,705,786.00 - 70,703,639.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.43 -2.78 -3.28 - -0.87
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -345.10% -655.74% -105.98% -50.51% -14.21% 56.26%
EBIT Growth		 0.00% -345.77% -682.19% -100.72% -50.82% -14.22% 55.82%
NOPAT Growth		 0.00% -345.77% -682.19% -100.72% -50.82% -14.22% 42.03%
Net Income Growth		 0.00% -344.41% -680.75% -96.86% -43.29% -18.06% 55.36%
EPS Growth		 0.00% -155.00% -241.18% -60.92% -22.86% -11.34% 69.19%
Operating Cash Flow Growth		 0.00% 0.00% -694.75% -76.13% -54.75% -24.12% 41.31%
Free Cash Flow Firm Growth		 0.00% 0.00% -1,018.95% -50.98% -69.32% -19.51% 61.41%
Invested Capital Growth		 0.00% 0.00% 550.93% -243.35% -64.55% 11.55% -271.17%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -34.16% -17.55% -9.51% 4.88% 37.78%
EBIT Q/Q Growth		 0.00% 0.00% -36.93% -16.01% -9.60% 4.79% 37.51%
NOPAT Q/Q Growth		 0.00% 0.00% -36.93% -16.01% -9.60% 4.79% 18.02%
Net Income Q/Q Growth		 0.00% 0.00% -36.94% -14.89% -8.89% 3.88% 35.43%
EPS Q/Q Growth		 0.00% 0.00% -10.13% -15.70% -2.69% 4.01% 50.42%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -59.09% -7.40% -2.81% -6.36% 18.58%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -5.67% -1.50% -8.94% 24.86%
Invested Capital Q/Q Growth		 0.00% 0.00% 1,186.86% -52.67% -5,328.10% 42.71% 16.35%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.25% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 99.94% 99.76% 97.84% 92.96% 96.08% 97.08%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -8.74% -34.68% -56.96% -84.42% -125.38% -152.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -982.30% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -0.74% -26.62% -56.96% -84.42% -125.38% -152.35%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -103.00% -23.25% -75.39% 0.00% -268.41% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.84 -3.73 -29 -59 -88 -101 -58
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -5.17% -10.46% -16.13% -19.93% -31.86% -5.83%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -53.94% -52.17% -195.55% -197.82%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.20 -5.33 -42 -84 -126 -144 -64
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.20 -5.32 -40 -83 -125 -142 -62
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 29.60 1.21 2.28 3.06 2.73 2.97
Price to Tangible Book Value (P/TBV)		 0.00 29.60 1.21 2.28 3.06 2.73 2.97
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 12.09 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.01 -0.99 -1.01 -1.05 -1.07 -1.41
Leverage Ratio		 0.00 1.03 1.04 1.10 1.19 1.27 1.71
Compound Leverage Factor		 0.00 1.03 1.03 1.07 1.10 1.22 1.66
Debt to Total Capital		 0.00% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 91.46% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 8.48% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 11.59 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 16.54 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 57.40 18.75 4.52 7.25 -9.06 -11.55
Noncontrolling Interest Sharing Ratio		 0.00% 91.51% 23.25% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 38.43 38.08 6.17 7.84 3.15 5.23
Quick Ratio		 0.00 38.11 37.42 5.92 7.74 2.69 5.03
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -2.98 -33 -50 -85 -102 -39
Operating Cash Flow to CapEx		 0.00% -8,743.14% -1,117.57% -6,059.90% -2,866.23% -33,119.89% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -0.75 3.39 -4.86 -8.00 -7.08 -26
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.75 4.14 -8.25 -3.14 0.92 -19
Enterprise Value (EV)		 0.00 147 41 134 341 82 32
Market Capitalization		 153 153 216 248 518 141 88
Book Value per Share		 $0.00 $0.49 $6.16 $3.69 $4.74 $1.42 $0.42
Tangible Book Value per Share		 $0.00 $0.49 $6.16 $3.69 $4.74 $1.42 $0.42
Total Capital		 0.00 61 179 109 169 52 30
Total Debt		 0.00 0.04 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -62 -175 -113 -177 -59 -56
Capital Expenditures (CapEx)		 0.00 0.05 3.17 1.03 3.37 0.36 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.06 -1.59 -15 -21 -12 -8.86
Debt-free Net Working Capital (DFNWC)		 0.00 61 172 99 156 47 47
Net Working Capital (NWC)		 0.00 61 172 99 156 47 47
Net Nonoperating Expense (NNE)		 0.36 1.60 12 23 29 38 3.34
Net Nonoperating Obligations (NNO)		 0.00 -62 -175 -113 -177 -59 -56
Total Depreciation and Amortization (D&A)		 0.00 0.01 1.47 0.84 1.52 1.75 1.41
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($3.44) ($3.83) ($1.18)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 34.11M 36.11M 52.23M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($3.44) ($3.83) ($1.18)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 34.11M 36.11M 52.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 35.89M 37.57M 72.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.84 -3.73 -29 -59 -88 -101 -57
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Biomea Fusion

This table displays calculated financial ratios and metrics derived from Biomea Fusion's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 35,631,576.00 35,705,786.00 35,889,360.00 35,944,584.00 36,210,167.00 - 37,572,250.00 37,572,250.00 59,508,518.00 70,703,639.00 72,299,440.00
DEI Adjusted Shares Outstanding		 35,631,576.00 35,705,786.00 35,889,360.00 35,944,584.00 36,210,167.00 - 37,572,250.00 37,572,250.00 59,508,518.00 70,703,639.00 72,299,440.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.80 -0.98 -1.09 -1.04 -0.91 - -0.78 -0.55 -0.28 0.07 -0.17
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -31.76% -41.48% -33.30% -44.73% -9.46% 19.79% 28.16% 45.34% 39.36% 60.57% 55.14%
EBIT Growth		 -32.51% -42.06% -36.72% -40.64% -9.38% 19.43% 27.64% 45.30% 38.88% 61.03% 57.01%
NOPAT Growth		 -32.51% -42.06% -36.72% -40.64% -9.38% 19.43% 27.64% 45.30% 38.88% 44.33% 57.01%
Net Income Growth		 -24.20% -37.81% -34.46% -49.76% -15.33% 16.00% 25.09% 44.36% 49.96% 115.74% 57.82%
EPS Growth		 -2.56% -10.34% -11.22% -47.14% -13.75% 16.67% 26.61% 50.49% 70.33% 150.00% 78.75%
Operating Cash Flow Growth		 -42.30% -13.05% -33.21% -26.46% -5.51% -31.38% 19.87% 41.15% 54.20% 53.53% 54.54%
Free Cash Flow Firm Growth		 -85.16% -126.71% -10.22% 20.12% 54.92% 4.42% -6.09% 125.51% 139.55% 133.97% 142.56%
Invested Capital Growth		 104.81% -64.55% -214.51% -794.85% -8,171.24% 11.55% 24.84% -195.81% -154.21% -271.17% -251.43%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -12.56% -20.22% -7.40% 0.42% 14.87% 11.90% 3.81% 24.24% 5.55% 42.72% -9.44%
EBIT Q/Q Growth		 -12.52% -19.95% -10.00% 5.26% 12.49% 11.65% 1.20% 28.39% 2.21% 43.67% -9.00%
NOPAT Q/Q Growth		 -12.52% -19.95% -10.00% 5.26% 12.49% 11.65% 1.20% 28.39% 2.21% 19.53% 23.70%
Net Income Q/Q Growth		 -14.21% -22.71% -11.97% 4.57% 12.04% 10.63% 0.14% 29.12% 20.89% 128.11% -367.65%
EPS Q/Q Growth		 -14.29% -20.00% -13.54% 5.50% 11.65% 12.09% 0.00% 36.25% 47.06% 248.15% -142.50%
Operating Cash Flow Q/Q Growth		 7.41% 4.44% -40.25% -1.91% 22.75% -18.98% 14.45% 25.15% 39.88% -20.71% 16.30%
Free Cash Flow Firm Q/Q Growth		 -24.44% 8.47% 4.58% 26.50% 29.76% -94.04% -5.91% 117.67% 8.89% 66.67% 32.67%
Invested Capital Q/Q Growth		 -89.05% -5,328.10% -24.68% 2.67% -27.22% 42.71% -5.95% -283.06% -9.33% 16.35% -0.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.36% 93.45% 95.13% 95.83% 96.32% 97.43% 98.49% 97.48% 78.86% -39.35% 96.63%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -65.21% -84.42% -116.52% -85.09% -104.51% -125.38% -156.81% -170.54% -209.00% -152.35% -189.14%
Cash Return on Invested Capital (CROIC)		 -54,833.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -65.21% -84.42% -116.52% -85.09% -104.51% -125.38% -156.81% -170.54% -209.00% -152.35% -189.14%
Return on Equity Simple (ROE_SIMPLE)		 -53.95% 0.00% -94.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -22 -26 -29 -27 -24 -21 -21 -15 -15 -12 -8.94
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.99% -6.02% -8.91% -5.97% -6.23% -7.00% -9.33% -6.88% -2.72% 28.54% -8.37%
Return On Investment Capital (ROIC_SIMPLE)		 - -15.44% -21.24% -26.19% -31.36% -40.82% -72.38% -54.14% -93.24% -39.66% -47.77%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -31 -37 -41 -39 -34 -30 -30 -21 -21 -12 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -31 -37 -40 -39 -34 -30 -28 -22 -20 -12 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.46 3.06 3.97 1.56 4.81 2.73 2.78 2.46 7.70 2.97 5.91
Price to Tangible Book Value (P/TBV)		 2.46 3.06 3.97 1.56 4.81 2.73 2.78 2.46 7.70 2.97 5.91
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1,900.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.05 -1.06 -1.03 -1.04 -1.07 -1.11 -1.29 -1.48 -1.41 -1.71
Leverage Ratio		 1.12 1.19 1.29 1.17 1.22 1.27 1.36 1.59 1.81 1.71 2.14
Compound Leverage Factor		 1.02 1.11 1.22 1.12 1.17 1.23 1.34 1.55 1.43 -0.67 2.07
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.75 8.72 7.38 -0.47 1.53 -4.35 -10.01 -7.67 -10.19 -8.62 -11.48
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.49 7.84 5.84 4.62 3.39 3.15 2.25 3.68 3.18 5.23 4.98
Quick Ratio		 12.28 7.74 5.74 4.50 3.19 2.69 1.81 3.20 3.00 5.03 4.81
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -23 -22 -16 -11 -22 -23 4.11 4.48 7.47 9.91
Operating Cash Flow to CapEx		 -61,279.49% -285,462.50% -91,514.29% -55,327.12% -13,557.53% -36,590.24% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.15 -8.00 -9.97 -9.71 -12 -7.08 -7.50 -29 -31 -26 -26
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.34 -3.14 -6.80 -11 -13 0.92 2.48 -19 -19 -19 -19
Enterprise Value (EV)		 291 341 391 48 277 82 44 11 73 32 66
Market Capitalization		 490 518 537 162 366 141 80 68 120 88 111
Book Value per Share		 $5.60 $4.74 $3.77 $2.89 $2.10 $1.42 $0.79 $0.73 $0.26 $0.42 $0.26
Tangible Book Value per Share		 $5.60 $4.74 $3.77 $2.89 $2.10 $1.42 $0.79 $0.73 $0.26 $0.42 $0.26
Total Capital		 200 169 135 104 76 52 29 28 16 30 19
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -199 -177 -145 -114 -88 -59 -36 -56 -47 -56 -45
Capital Expenditures (CapEx)		 0.04 0.01 0.04 0.06 0.19 0.08 0.00 0.00 0.00 0.00 -0.55
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -21 -23 -23 -22 -12 -11 -9.13 -13 -8.86 -8.04
Debt-free Net Working Capital (DFNWC)		 186 156 122 91 66 47 25 47 34 47 37
Net Working Capital (NWC)		 186 156 122 91 66 47 25 47 34 47 37
Net Nonoperating Expense (NNE)		 6.65 8.75 10 10 8.96 8.25 8.46 5.85 1.84 -16 3.40
Net Nonoperating Obligations (NNO)		 -199 -177 -145 -114 -88 -59 -36 -56 -47 -56 -45
Total Depreciation and Amortization (D&A)		 0.42 0.42 1.42 -0.58 0.44 0.47 1.23 -0.30 0.43 0.05 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.80) ($0.96) ($1.09) ($1.03) ($0.91) ($0.80) ($0.80) ($0.51) ($0.27) $0.40 ($0.17)
Adjusted Weighted Average Basic Shares Outstanding		 35.65M 34.11M 35.89M 36.04M 36.22M 36.11M 36.63M 40.63M 59.85M 52.23M 72.30M
Adjusted Diluted Earnings per Share		 ($0.80) ($0.96) ($1.09) ($1.03) ($0.91) ($0.80) ($0.80) ($0.51) ($0.27) $0.40 ($0.17)
Adjusted Weighted Average Diluted Shares Outstanding		 35.65M 34.11M 35.89M 36.04M 36.22M 36.11M 36.63M 40.63M 59.85M 52.23M 72.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.71M 35.89M 35.94M 36.21M 36.24M 37.57M 37.57M 59.51M 70.70M 72.30M 72.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -26 -29 -27 -24 -21 -21 -15 -13 -8.20 -8.94
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Biomea Fusion (NASDAQ: BMEA) continues to look like a development-stage biotech with no product revenue and substantial cash burn. Over the last four years, the company has moved from a very cash-rich balance sheet to a much tighter liquidity position, while operating losses have remained large and consistent. The latest quarter also shows a return to negative net income and negative operating cash flow.

  • Biomea ended Q1 2026 with $44.7 million in cash and equivalents plus $0.4 million in restricted cash, giving it a visible near-term liquidity cushion.
  • The company still reported positive common equity of $18.7 million in Q1 2026, so the balance sheet has not yet tipped into deficit territory.
  • Interest and investment income of $430,000 in Q1 2026 helped offset a small portion of operating losses.
  • R&D spending in Q1 2026 was $9.1 million, lower than several earlier quarters, which may suggest a more controlled spending pace than in 2024.
  • There was no revenue in any quarter shown, so the company is still entirely dependent on future clinical and commercial execution.
  • Q1 2026 operating expenses totaled $12.8 million, with SG&A of $3.6 million and R&D of $9.1 million.
  • The Q1 2026 cash flow statement shows a non-cash adjustment of $1.7 million, but operating cash flow was still negative, so the business remains cash-burning.
  • Q1 2026 net loss was $12.3 million, or $0.17 per share, showing that losses remain significant even after recent expense reductions.
  • Operating cash flow in Q1 2026 was negative $11.7 million, which means the company is still consuming cash at a meaningful rate.
  • Biomea’s cash balance has fallen sharply from $199.1 million in Q3 2023 to $44.7 million in Q1 2026, a major decline that raises financing risk over time.

Longer-term trend: Biomea’s quarterly losses have generally remained in the $12 million to $39 million range over the period shown, while operating cash outflows have often exceeded $20 million per quarter. The company did benefit from equity raises in 2024 and 2025, but dilution has been meaningful, with weighted average basic shares rising from roughly 35.9 million in Q1 2024 to 72.3 million in Q1 2026 in the latest reported quarter.

Bottom line: The financial picture is still typical of an early-stage biotech: no revenue, recurring losses, and dependence on cash reserves and capital markets. The main positive is that Biomea still has cash on hand and positive equity, but the combination of ongoing burn and a much smaller cash balance than a few years ago keeps the risk profile high for retail investors.

07/26/26 10:19 PM ETAI Generated. May Contain Errors.

Biomea Fusion Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Biomea Fusion's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Biomea Fusion's net income appears to be on an upward trend, with a most recent value of -$61.80 million in 2025, rising from -$1.20 million in 2019. The previous period was -$138.43 million in 2024. View Biomea Fusion's forecast to see where analysts expect Biomea Fusion to go next.

Biomea Fusion's total operating income in 2025 was -$83.51 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $83.51 million

Over the last 6 years, Biomea Fusion's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Biomea Fusion's total liabilities were at $29.02 million at the end of 2025, a 2.3% increase from 2024, and a 1,692.5% increase since 2020.

In the past 5 years, Biomea Fusion's cash and equivalents has ranged from $55.81 million in 2025 to $176.87 million in 2023, and is currently $55.81 million as of their latest financial filing in 2025.

Over the last 6 years, Biomea Fusion's book value per share changed from 0.00 in 2019 to 0.42 in 2025, a change of 41.8%.


Related Companies

Financial statements for NASDAQ:BMEA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Control 100 shares without spending thousands of dollars
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
BlackRock's $2.8B Clue (most investors missed)
BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...
Awesomely | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel